A protocol is updated mid-study to add an additional procedure about which data needs to be collected. Which of these statements applies?
Answer(s): B
When a protocol is amended mid-study, resulting in additional data collection requirements, the Data Management Plan (DMP) must be updated accordingly and all relevant stakeholders must be notified.According to the GCDMP (Chapter: Data Management Planning and Study Start-up), the DMP is a living document that defines all data management processes for a clinical study. It must accurately reflect the current data flow, CRF design, validation procedures, and reporting structure. Any protocol amendments affecting data capture, structure, or analysis require immediate DMP revision and distribution to ensure alignment across data management, clinical, and biostatistics teams. Failure to update and communicate DMP changes can lead to misalignment in data handling and introduce compliance risks during audits or inspections. Therefore, Option B is correct: the DMP must be updated and the change communicated to all stakeholders (e.g., sponsor, CRO, clinical operations, biostatistics).
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Plan (DMP), Section 5.3 Maintaining and Updating the DMPICH E6 (R2) Good Clinical Practice, Section 5.5.3 Documentation of Protocol Changes and Data Handling ProceduresFDA Guidance for Industry: Computerized Systems Used in Clinical Investigations Section on Data Management Documentation
An external organization has been hired to manage SAE follow-up for a large study. Which of the following would be used as guidance for exchange of the SAE data between the EDC system and the vendor's safety management system?
Answer(s): C
The Individual Case Safety Report (ICSR) is the standard format used globally for the exchange of Serious Adverse Event (SAE) data between clinical data management systems (EDC) and safety management systems.According to ICH E2B(R3) and Good Clinical Data Management Practices (GCDMP, Chapter: Safety Data Management and SAE Reconciliation), the ICSR provides the data structure and content standards for electronic transmission of safety data, including patient demographics, event details, outcomes, and product information. It ensures interoperability between systems by defining standardized message elements and controlled terminologies.Other options are not applicable:A . Medical Document for Regulatory Activities (MDRA) is not a recognized standard. B . Biomedical Research Domain Model (BRIDG) provides conceptual modeling but not data exchange guidance.D . SDTM is used for regulatory submission datasets, not real-time SAE exchange. Thus, option C (Individual Case Safety Report) is correct, as it defines the internationally accepted electronic format for SAE data exchange between safety and clinical databases.
(CCDM-Verified Sources)SCDM GCDMP, Chapter: Safety Data Management and SAE Reconciliation, Section 4.3 SAE Data Exchange and StandardsICH E2B(R3): Electronic Transmission of Individual Case Safety Reports FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format -- Postmarketing ICSRs (2014)
Which database table structure is most appropriate for vital signs data collected at every-other visit for each patient in a study?
In a relational clinical database, the most efficient and normalized structure for data collected repeatedly over time--such as vital signs--is one record per patient per visit. Each patient will have multiple records, one for each visit when vital signs are assessed. This structure supports:Time-based analysis (e.g., trends across visits),Accurate data linkage with visit-level metadata, andEfficient querying for longitudinal data.According to the GCDMP (Chapter: Database Design and Build), the relational design principle dictates that data should be stored at the lowest unique level of observation. Since vital signs vary by both patient and visit, the combination of patient ID + visit ID forms a unique key for each record. Option A (per visit) lacks patient identification, while options B and D aggregate data too broadly, losing temporal detail.Thus, option C (One record per patient per visit) correctly represents the normalized design structure.
(CCDM-Verified Sources)SCDM GCDMP, Chapter: Database Design and Build, Section 4.2 Normalization and Table Structure CDISC SDTM Implementation Guide, Section 5.3 Visit-Level and Observation-Level Data Structures ICH E6(R2) GCP, Section 5.5.3 Data Handling Principles
A site study coordinator attempts to make an update in a study database in an EDC system after lock.What occurs?
Once a clinical database is locked, it becomes read-only -- no further data modifications can be made by any users, including site personnel. This ensures that the data are finalized, consistent, and auditable for statistical analysis and regulatory submission. According to the GCDMP (Chapter: Database Lock and Archiving), the lock process involves freezing the database to prevent accidental or unauthorized changes. After lock, access permissions are restricted, and all edit and update functions are disabled. If any corrections are required post-lock, the database must be unlocked under controlled procedures (with full audit trail documentation). Thus, option C -- The site study coordinator is not able to make the change -- correctly reflects standard EDC functionality and regulatory compliance.
(CCDM-Verified Sources)SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.2 Database Lock Procedures and ControlsICH E6(R2) GCP, Section 5.5.3 Data Integrity and Audit Trail RequirementsFDA 21 CFR Part 11 Controls for Electronic Records and System Lock Functions
In a physical therapy study, range of motion is assessed by a physical therapist at each site using a study-provided goniometer. Which is the most appropriate quality control method for the range of motion measurement?
Answer(s): D
In this scenario, the variable of interest--range of motion (ROM)--is a clinically measured, observer- dependent variable. The accuracy and reliability of such data depend primarily on the precision and consistency of the measurement technique, not merely on data entry validation. Therefore, the most appropriate quality control (QC) method is independent verification of the measurement by a second qualified assessor during the visit (Option D).According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Quality Assurance and Control), quality control procedures must be tailored to the nature of the data. For clinically assessed variables, especially those involving human judgment (e.g., physical measurements, imaging assessments, or subjective scoring), real-time verification by an independent qualified assessor ensures that data are valid and reproducible at the point of collection. This approach directly addresses measurement bias, observer variability, and instrument misuse, which are primary sources of data error in clinical outcome assessments. Other options, while valuable, address only data consistency or plausibility after collection:Option A (comparison to previous visit) and Option C (reviewing data listings) are retrospective data reviews, suitable for identifying trends but not preventing measurement error. Option B (programmed edit checks) detects only extreme or impossible values, not measurement inaccuracies due to technique or observer inconsistency. The GCDMP and ICH E6 (R2) Good Clinical Practice guidelines emphasize that data quality assurance should begin at the source, through standardized procedures, instrument calibration, and dual assessments for observer-dependent measures. Having an independent second assessor ensures inter-rater reliability and provides direct confirmation that the recorded value reflects an accurate and valid measurement.
(CCDM-Verified Sources)Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.4 Measurement Quality and Verification ICH E6 (R2) Good Clinical Practice, Section 2.13 Quality Systems and Data Integrity FDA Guidance for Industry: Patient-Reported Outcome Measures and Clinical Outcome Assessment Data, Section 5.3 Quality Control of Clinician-Assessed DataSCDM GCDMP Chapter: Source Data Verification and Quality Oversight Procedures
Post your Comments and Discuss SCDM CCDM exam prep with other Community members:
Our website is free, but we have to fight against AI bots and content theft. We're sorry for the inconvenience caused by these security measures. You can access the rest of the CCDM content, but please register or login to continue.